Cargando…
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: Addressing treatment outside the current NICE guidance
Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the curr...
Autores principales: | Chiu, Yee, Ostor, Andrew J. K., Hammond, Anthony, Sokoll, Katharina, Anderson, Marina, Buch, Maya, Ehrenstein, Michael R., Gordon, Patrick, Steer, Sophia, Bruce, Ian N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362712/ https://www.ncbi.nlm.nih.gov/pubmed/22271229 http://dx.doi.org/10.1007/s10067-011-1936-6 |
Ejemplares similares
-
Abatacept in the treatment of rheumatoid arthritis
por: Buch, Maya H, et al.
Publicado: (2008) -
Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience
por: Maccora, Ilaria, et al.
Publicado: (2022) -
Mandatory implementation of NICE Guidelines for the care of bipolar disorder and other conditions in England and Wales
por: Morriss, Richard
Publicado: (2015) -
HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales
por: Thokala, Praveen, et al.
Publicado: (2020) -
Diagnosis and treatment of advanced breast cancer: summary of NICE guidance
por: Murray, N, et al.
Publicado: (2009)